Harpoon Therapeutics, Inc. clinical trials
Acquired by Merck & Co., Inc, Mar 11, 2024 · source ↗
The registry lists 4 studies whose lead sponsor is Harpoon Therapeutics, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 24, 2026.
- 4studies on the registry
- 0open to participants now
- 1reach primary completion within a year
Before and after it joined Merck & Co., Inc
- First submitted before Harpoon Therapeutics, Inc. became part of Merck & Co., Inc
- 4
- First submitted after Harpoon Therapeutics, Inc. became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Harpoon Therapeutics, Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 1
Coming up
1 of Harpoon Therapeutics, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 4 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 18
- 19
- 220
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All Merck & Co., Inc studies →
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingNCT04471727Phase 1/2
Sponsor listed in the registry: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Harpoon Therapeutics, Inc. became part of Merck & Co., Inc
- Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)Active, not recruitingNCT04184050Phase 1
Sponsor listed in the registry: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Harpoon Therapeutics, Inc. became part of Merck & Co., Inc
- Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin ExpressionCompletedNCT03872206Phase 1
Sponsor listed in the registry: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Harpoon Therapeutics, Inc. became part of Merck & Co., Inc
- Study of HPN424 in Patients With Advanced Prostate CancerTerminatedNCT03577028Phase 1/2
Sponsor listed in the registry: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Harpoon Therapeutics, Inc. became part of Merck & Co., Inc